Monday, May 2, 2016 5:49:00 AM PDT | VentureDeal
South San Francisco, California -- Biotechnology company FLX Bio has raised $50 million in its second round of institutional venture capital financing.
FLX Bio is developing immuno-oncology agents that fight cancer by activating the body's immune system. Investors in the round included The Column Group, Topspin Partners, Kleiner Perkins Caufield & Byers and Celgene. The company said it would use the funding to support further discovery and development of its pipeline of compounds. FLX Bio also said it would use the funding to advance its lead candidate FLX925 through a proof of concept study in patients with acute myeloid leukemia.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
